Thymosin Alpha-1 (Tα1) is a 28 amino acid acetylated peptide corresponding to the N-terminal fragment of prothymosin alpha. First isolated and sequenced by Allan Goldstein and colleagues in the 1970s, Tα1 has been commercially available as Zadaxin (thymalfasin) since 1985 and has been approved or registered in more than 35 countries.
Innate and Adaptive Immune System Research
Research has extensively examined Thymosin Alpha-1's interactions with both innate and adaptive immune system components. Studies have documented its effects on dendritic cell maturation, NK cell activation, and T-helper cell differentiation in preclinical models and clinical research settings.
Toll-Like Receptor and Pattern Recognition Research
Research has identified Thymosin Alpha-1's interactions with toll-like receptors (TLR2, TLR4, TLR9) as a key mechanism underlying its immunomodulatory effects, examining its capacity to enhance innate immune recognition.
Clinical Immunology Research Background
Thymosin Alpha-1's extensive clinical research history includes studies in cancer immunology, infectious disease models, and immunodeficiency research, with substantial Phase 2 and Phase 3 clinical data across multiple research indications.
• Goldstein AL et al. (1977). Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences, 74(2), 725–729.
• Garaci E et al. (2012). Thymosin alpha 1 in the treatment of cancer. Annals of the New York Academy of Sciences, 1270, 26–31.
